MACI® (MACI Arthro™)
Symptomatic cartilage defects of the knee (adults)
Approved/CommercialFDA approved; label expanded in August 2024 for arthroscopic delivery for defects up to 4 cm².
Key Facts
Indication
Symptomatic cartilage defects of the knee (adults)
Phase
Approved/Commercial
Status
FDA approved; label expanded in August 2024 for arthroscopic delivery for defects up to 4 cm².
Company
About Vericel
Vericel is a leader in advanced cell therapies, with a mission to improve the lives of patients with serious conditions through innovative, personalized treatments. The company has achieved significant milestones, including FDA approval for the arthroscopic delivery of its flagship MACI product and the expansion of NexoBrid's label to include pediatric burn patients. Its strategic direction focuses on commercial execution of its approved products, pipeline development, and leveraging its cell therapy manufacturing expertise to capitalize on the rapidly growing regenerative medicine market.
View full company profile